NCL Technology Ventures
VC Fund
London, United Kingdom
NCL Technology Ventures is a VC fund in London focused on Health Care and Medical. NCL is a specialist investment manager and advisory boutique that acts as a commercialisation engine for disruptive technology SMEs. NCL started in 2010 as Narec Capital, a joint venture with the UK’s National Renewable Energy Centre. Its primary purpose was to commercialise the IP that came through the centre of excellence, on behalf of UK Plc.NCL exploits the commercialisation stage funding gap by identifying truly high potential technologies and providing them with both the resource and institutional investment capital required to turn them into high performing SMEs. They are true venture managers with an inherent technology backbone.Guided by a highly experienced investment committee and leading scientific advisory board, NCL have deployed over $55M into the health sector, as a lead investor, over the last 3 years.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 38%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries NCL Technology Ventures invests in
Stages NCL Technology Ventures invests in
Countries NCL Technology Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 8 (62%)
- Medical 4 (31%)
- Biotechnology 4 (31%)
- Therapeutics 3 (23%)
- Medical Device 3 (23%)
Stage
- Seed 6 (46%)
- Series A 3 (23%)
- Series B 1 (8%)
- Funding Round 1 (8%)
- Venture - Series Unknown 1 (8%)
Country
- United Kingdom 8 (62%)
- Israel 1 (8%)
- Ireland 1 (8%)
- United States 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Graham Hutchins
Chief Operating Officer
|
Chief Operating Officer | Total investments: 0 | Find email | |
Jermey Biggs
Founder & CEO
|
Founder & CEO | Total investments: 0 | Find email | |
Jonathan Synett
Chief Investment Officer
|
Chief Investment Officer | Total investments: 7 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ampersand is pioneering the development of behavioural science based digital medicines for people living with long term inflammatory conditions. We deliver measurable improvements in mental health and quality of life for patients and significant, well-evidenced savings for healthcare providers. | Jul 06, 2020 | ||
| Curesponse is a medical company developing a three-dimensional tissue culture system for modeling cancer growth and drug response. The company's technology represents the next step in personalized cancer medicine, moving prediction capabilities beyond genomics and into the world of functional response on living patient cells. The platformpreserves the cancer tissue architecture, including the vasculature and immune system, accurately reflecting the cancer growth found in the body.Curesponse’s cutting edge functional platform will match the correct drug to the patient's cancer, improving survival and saving unnecessary medical interventions. The company is harnessing the technology to create a personalized cancer diagnostic assay that can be used to determine the drug response for a specific individual's tumor type. | $6M / Series A / Jun 05, 2020 | ||
| Ampersand is pioneering the development of behavioural science based digital medicines for people living with long term inflammatory conditions. We deliver measurable improvements in mental health and quality of life for patients and significant, well-evidenced savings for healthcare providers. | Jul 01, 2019 | ||
| Emteq creates facial wearables - glasses - that understand the expressions and emotions of the wearer, enabling improved Human-Computer Interaction, Human Augmentation and Emotion Analytics through advanced AI techniques. Emteq was founded by Graeme Cox and Charles Nduka in 2015 and is headquartered in Brighton, East Sussex. | $1.5M / Seed / Apr 10, 2019 | ||
| Azadyne’s novel approach to treating autoimmune disease focuses on an unexplored pathway in the body and is based on research conducted at Trinity by Associate Professor in Biochemistry Vincent Kelly, Professor of Synthetic Chemistry Professor Stephen Connon and assistant Professor in Chemistry John Michael Southern. | $2M / Seed / Mar 27, 2019 | ||
| Revolo Biotherapeutics has developed therapies that achieve superior long-term disease remission from less frequent chronic dosing and without suppression of the immune system. Its mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission.Revolo Biotherapeuticswas founded in 2011 and formerly known as Immune Regulation. | Series A / Nov 22, 2018 | ||
| Sana Health is an audio-visual neuromodulation device, that provides anxiety relief on-demand - multiple applications in pain and mental health, 2 pivotal studies are underway in Fibromyalgia (FDA designated breakthrough device) and Neuropathic Pain. Anxiety and PTSD trials starting in Q2 2022, DoD grant for PTSD.SOSV, Founders Fund, Noetic Fund,Harmonix, Dreamit, Esplanade, Bridge Builders Collective, Menlo Ventures. | $4.3M / Seed / Jul 17, 2018 | ||
Andiamo
|
Custom medical wearables platform | Seed / Mar 01, 2018 | |
| Peptinnovate Limited, is a U.K. drug development company developing a ‘first in class’ immune regulating therapy for inflammatory diseases. | $3.4M / Series A / Jun 17, 2017 | ||
| Coomtech Ltd are a sustainable energy technology company, that have developed a novel process for drying Biomass and Low Rank Coal. The technology significantly improves the efficiency of the combustion process, leading to vast industry cost savings and lower CO2 emissions. | Series B / Apr 24, 2017 | ||
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does NCL Technology Ventures invest in?
NCL Technology Ventures invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series A stage. Most of the 13 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact NCL Technology Ventures?
Public channels for NCL Technology Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at NCL Technology Ventures?
The team at NCL Technology Ventures includes Graham Hutchins (Chief Operating Officer), Jermey Biggs (Founder & CEO) and Jonathan Synett (Chief Investment Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
